Core Insights - Avidity Biosciences, Inc. (NASDAQ:RNA) is highlighted as a top stock to buy for the next three months according to hedge funds, with a reiterated Buy rating and a price target of $96 from Cantor Fitzgerald [1][2] Business Updates - The company reported significant progress in three late-stage neuromuscular programs targeting Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy [2][3] - The FDA granted Breakthrough Therapy designation for Delpacibart Zotadirsen, with plans to submit a Biologics License Application for del-zota by the end of 2025 [3] Financial Performance - Avidity Biosciences, Inc. achieved an 88.12% increase in collaboration revenue, reaching $3.85 billion, surpassing consensus estimates by $2.24 million [4]